- Trial phase
- Approved (marketed); Phase 3 programs ongoing/completed (PROTEUS final analysis reported; ATLAS results pending)
- Time to market
- Already on the market (FDA approved Feb 2018 for nmCRPC, expanded Sep 2019 for mCSPC). A potential perioperative label expansion from PROTEUS has no confirmed filing or approval date yet.
- Why 3/10
- No scheduled hard, dated catalyst (no pending PDUFA, sNDA, or confirmed pivotal readout date) for ERLEADA in the next ~12 months, ATLAS Phase 3's estimated primary completion (June 30, 2026) has passed with results unreported and any PROTEUS-based label-expansion filing is unconfirmed, and the drug is already approved and commercialized, so it scores 3 as a large but non-binary product inside a mega-cap.
Watch for (1) a J&J submission to FDA of the PROTEUS perioperative (high-risk localized prostate cancer) data, that would be the next real catalyst and would open an earlier-stage, larger patient market; and (2) the ATLAS Phase 3 readout (apalutamide + radiation), whose primary completion was estimated for mid-2026 and results are still unreported. Neither is dated, so don't trade JNJ on ERLEADA alone, at ~$3.6B of annual sales it is roughly 4% of J&J revenue, and the active-ingredient patent expiry around September 2030 caps the long-term growth story.
Price Chart
Executive Summary
ERLEADA (apalutamide) is Johnson & Johnson's oral prostate-cancer drug, approved since 2018 for non-metastatic castration-resistant prostate cancer and since 2019 for metastatic castration-sensitive prostate cancer. It is a commercial success, 2025 sales of $3.57B (+19.2% YoY) and Q1 2026 sales of $949M (+23.1% YoY), and clinically it keeps winning: the PROTEUS Phase 3 trial (ASCO 2026/NEJM) showed adding apalutamide before and after prostatectomy cut metastasis-or-death risk by ~20% in high-risk localized disease, positioning it for a possible label expansion into an earlier-stage market. However, there is no dated regulatory catalyst in the next 12 months (the ATLAS radiation-trial readout is pending but undated), competition within the ARPI class is intense, and the active-ingredient patent expires around September 2030, so the drug is a steady growth asset, not a swing factor for a ~$400B mega-cap.
How It Works
ERLEADA is an oral pill that blocks the androgen receptor, the protein that prostate cancer cells use to sense testosterone and other male hormones that fuel their growth. By jamming that signal, it slows or stops the cancer. It belongs to a class called androgen receptor pathway inhibitors (ARPIs), the same family as Pfizer/Astellas' Xtandi (enzalutamide) and Bayer's Nubeqa (darolutamide).
Trial Status
PROTEUS Phase 3 (perioperative apalutamide + ADT around prostatectomy, n=2109) final analysis was presented at ASCO 2026 and published in NEJM, showing improved metastasis-free survival and a reported ~20% reduction in risk of metastasis or death in high-risk localized/locally advanced prostate cancer. ATLAS Phase 3 (apalutamide + GnRH agonist + radiation, n=1503) is active but not recruiting; primary completion was estimated at June 30, 2026 and results have not yet been announced. A 2024 real-world head-to-head study showed ERLEADA beat enzalutamide on 24-month overall survival in mCSPC (23% lower risk of death).
The Two-Sided Case
Upcoming Catalysts
- Possible FDA sNDA submission of PROTEUS perioperative data (unconfirmed timing), the clearest next value catalyst.
- ATLAS Phase 3 topline results (apalutamide + radiation in high-risk localized disease), primary completion was estimated at June 30, 2026; results not yet announced.
- Quarterly sales updates: ERLEADA growth rate (Q2 2026 earnings already reported in July 2026; next reports follow J&J cadence).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
JOHNSON & JOHNSON 8-K JNJ ·Originating report